Search

Your search keyword '"Martínez López, Joaquín"' showing total 1,569 results
Start Over Author "Martínez López, Joaquín"
1,569 results on '"Martínez López, Joaquín"'

1. PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma

Author

Martinez-Verbo, Laura, Veselinova, Yoana, Llinàs-Arias, Pere, García-Prieto, Carlos A., Noguera-Castells, Aleix, Pato, Miguel L., Bueno-Costa, Alberto, Campillo-Marcos, Ignacio, Villanueva, Lorea, Oliver-Caldes, Aina, Cardus, Oriol, Salsench, Sergi V., García-Ortiz, Almudena, Valeri, Antonio, Rojas, Elizabeta A., Barrena, Naroa, Gutiérrez, Norma C., Prósper, Felipe, Agirre, Xabier, Fernández de Larrea, Carlos, Martínez-López, Joaquín, Ferrer, Gerardo, and Esteller, Manel

Published
2024
Full Text
View/download PDF

2. Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

Author

Lakhwani, Sunil, Mateos, María Victoria, Martínez-López, Joaquín, Paiva, Bruno, Rosiñol Dachs, Laura, Martínez, Rafael, Oriol, Albert, Bargay, Joan, González-Montes, Yolanda, Gironella, Mercedes, Encinas, Cristina, Martín, Jesús, Jarque, Isidro, Granell, Miquel, Abella, Eugenia, García-Mateo, Aránzazu, Hernández-Rivas, José Ángel, Ramila, Elena, Krsnik, Isabel, Casado Montero, Luis Felipe, De Arriba, Felipe, Palomera, Luis, Sampol, Antonia, Moraleda, José María, Casanova, María, Delgado, Pilar, Lafuente, Ana, Amutio, Elena, López-Martínez, Aurelio, Altés, Albert, Ruíz, M. Ángeles, Alegre, Adrián, Lopez-Anglada, Lucia, De La Cruz, Javier, Alonso Fernández, Rafael, Bladé Creixenti, Joan, Lahuerta, Juan-José, San-Miguel, Jesús, and Hernández, Miguel-Teodoro

Published
2024
Full Text
View/download PDF

3. Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study

Author

Pérez-Lamas, Lucía, de Paz Arias, Raquel, Díaz, Rosa Mª Ayala, Montero, Luis Felipe Casado, Payer, Ángel Ramírez, Sierra, Magdalena, Marín, Francisca Ferrer, López, Raúl Pérez, Cirici, Blanca Xicoy, Steegmann, Juan Luis, Gómez Casares, María Teresa, Martínez-López, Joaquín, and García-Gutiérrez, Valentín

Published
2024
Full Text
View/download PDF

4. Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications – a HARMONY study

Author

Hernández-Sánchez, Alberto, González, Teresa, Sobas, Marta, Sträng, Eric, Castellani, Gastone, Abáigar, María, Valk, Peter J. M., Villaverde Ramiro, Ángela, Benner, Axel, Metzeler, Klaus H., Azibeiro, Raúl, Tettero, Jesse M., Martínez-López, Joaquín, Pratcorona, Marta, Martínez Elicegui, Javier, Mills, Ken I., Thiede, Christian, Sanz, Guillermo, Döhner, Konstanze, Heuser, Michael, Haferlach, Torsten, Turki, Amin T., Reinhardt, Dirk, Schulze-Rath, Renate, Barbus, Martje, Hernández-Rivas, Jesús María, Huntly, Brian, Ossenkoppele, Gert, Döhner, Hartmut, and Bullinger, Lars

Published
2024
Full Text
View/download PDF

5. Author Correction: Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA

Author

Sánchez, Ricardo, Dorado, Sara, Ruíz-Heredia, Yanira, Martín-Muñoz, Alejandro, Rosa-Rosa, Juan Manuel, Ribera, Jordi, García, Olga, Jimenez-Ubieto, Ana, Carreño-Tarragona, Gonzalo, Linares, María, Rufián, Laura, Juárez, Alexandra, Carrillo, Jaime, Espino, María José, Cáceres, Mercedes, Expósito, Sara, Cuevas, Beatriz, Vanegas, Raúl, Casado, Luis Felipe, Torrent, Anna, Zamora, Lurdes, Mercadal, Santiago, Coll, Rosa, Cervera, Marta, Morgades, Mireia, Hernández-Rivas, José Ángel, Bravo, Pilar, Serí, Cristina, Anguita, Eduardo, Barragán, Eva, Sargas, Claudia, Ferrer-Marín, Francisca, Sánchez-Calero, Jorge, Sevilla, Julián, Ruíz, Elena, Villalón, Lucía, del Mar Herráez, María, Riaza, Rosalía, Magro, Elena, Steegman, Juan Luis, Wang, Chongwu, de Toledo, Paula, García-Gutiérrez, Valentín, Ayala, Rosa, Ribera, Josep-Maria, Barrio, Santiago, and Martínez-López, Joaquín

Published
2024
Full Text
View/download PDF

6. Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma

Author

Zugasti, Inés, Tormo-Ratera, Marta, Oliver-Caldés, Aina, Soler-Perromat, Juan Carlos, González-Calle, Verónica, Moreno, David F., Cabañas, Valentín, López-Muñoz, Nieves, Bartolomé-Solanas, Álvaro, Español-Rego, Marta, Reguera-Ortega, Juan Luis, Rosiñol, Laura, López-Corral, Lucía, Tovar, Natalia, Rodríguez-Lobato, Luis Gerardo, Alvarez Perez, Rosa Maria, Varea, Sara, Olesti, Eulàlia, Gomez-Grande, Adolfo, Frutos, Laura, Tamayo, Pilar, Juan, Manel, Moraleda, José M., Urbano-Ispizua, Álvaro, González-Navarro, E. Azucena, Martínez-López, Joaquín, Mateos, Maria-Victoria, Tomás, Xavier, Setoain, Xavier, and Fernández de Larrea, Carlos

Published
2025
Full Text
View/download PDF

8. Teclistamab in Relapsed or Refractory Multiple Myeloma

Author

Moreau, Philippe, Garfall, Alfred L, van de Donk, Niels WCJ, Nahi, Hareth, San-Miguel, Jesús F, Oriol, Albert, Nooka, Ajay K, Martin, Thomas, Rosinol, Laura, Chari, Ajai, Karlin, Lionel, Benboubker, Lotfi, Mateos, Maria-Victoria, Bahlis, Nizar, Popat, Rakesh, Besemer, Britta, Martínez-López, Joaquín, Sidana, Surbhi, Delforge, Michel, Pei, Lixia, Trancucci, Danielle, Verona, Raluca, Girgis, Suzette, Lin, Shun XW, Olyslager, Yunsi, Jaffe, Mindy, Uhlar, Clarissa, Stephenson, Tara, Van Rampelbergh, Rian, Banerjee, Arnob, Goldberg, Jenna D, Kobos, Rachel, Krishnan, Amrita, and Usmani, Saad Z

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Hematology, Immunotherapy, Rare Diseases, 6.1 Pharmaceuticals, 6.2 Cellular and gene therapies, Cancer, Antibodies, Bispecific, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, B-Cell Maturation Antigen, CD3 Complex, Humans, Injections, Subcutaneous, Multiple Myeloma, Neoplasm Recurrence, Local, Recurrence, T-Lymphocytes, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundTeclistamab is a T-cell-redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells. In the phase 1 dose-defining portion of the study, teclistamab showed promising efficacy in patients with relapsed or refractory multiple myeloma.MethodsIn this phase 1-2 study, we enrolled patients who had relapsed or refractory myeloma after at least three therapy lines, including triple-class exposure to an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody. Patients received a weekly subcutaneous injection of teclistamab (at a dose of 1.5 mg per kilogram of body weight) after receiving step-up doses of 0.06 mg and 0.3 mg per kilogram. The primary end point was the overall response (partial response or better).ResultsAmong 165 patients who received teclistamab, 77.6% had triple-class refractory disease (median, five previous therapy lines). With a median follow-up of 14.1 months, the overall response rate was 63.0%, with 65 patients (39.4%) having a complete response or better. A total of 44 patients (26.7%) were found to have no minimal residual disease (MRD); the MRD-negativity rate among the patients with a complete response or better was 46%. The median duration of response was 18.4 months (95% confidence interval [CI], 14.9 to not estimable). The median duration of progression-free survival was 11.3 months (95% CI, 8.8 to 17.1). Common adverse events included cytokine release syndrome (in 72.1% of the patients; grade 3, 0.6%; no grade 4), neutropenia (in 70.9%; grade 3 or 4, 64.2%), anemia (in 52.1%; grade 3 or 4, 37.0%), and thrombocytopenia (in 40.0%; grade 3 or 4, 21.2%). Infections were frequent (in 76.4%; grade 3 or 4, 44.8%). Neurotoxic events occurred in 24 patients (14.5%), including immune effector cell-associated neurotoxicity syndrome in 5 patients (3.0%; all grade 1 or 2).ConclusionsTeclistamab resulted in a high rate of deep and durable response in patients with triple-class-exposed relapsed or refractory multiple myeloma. Cytopenias and infections were common; toxic effects that were consistent with T-cell redirection were mostly grade 1 or 2. (Funded by Janssen Research and Development; MajesTEC-1 ClinicalTrials.gov numbers, NCT03145181 and NCT04557098.).

Published
2022

9. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee

Author

Lin, Yi, Qiu, Lugui, Usmani, Saad, Joo, Chng Wee, Costa, Luciano, Derman, Benjamin, Du, Juan, Einsele, Hermann, Fernandez de Larrea, Carlos, Hajek, Roman, Ho, P Joy, Kastritis, Efstathios, Martinez-Lopez, Joaquin, Mateos, Maria-Victoria, Mikhael, Joseph, Moreau, Philippe, Nagarajan, Chandramouli, Nooka, Ajay, O'Dwyer, Michael, Schjesvold, Fredrik, Sidana, Surbhi, van de Donk, Niels WCJ, Weisel, Katja, Zweegman, Sonja, Raje, Noopur, Otero, Paula Rodriguez, Anderson, Larry D, Jr, Kumar, Shaji, and Martin, Tom

Published
2024
Full Text
View/download PDF

10. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

Author

Dreyling, Martin, Fowler, Nathan Hale, Dickinson, Michael, Martinez-Lopez, Joaquin, Kolstad, Arne, Butler, Jason, Ghosh, Monalisa, Popplewell, Leslie, Chavez, Julio C., Bachy, Emmanuel, Kato, Koji, Harigae, Hideo, Kersten, Marie José, Andreadis, Charalambos, Riedell, Peter A., Ho, P. Joy, Pérez-Simón, José Antonio, Chen, Andy I., Nastoupil, Loretta J., von Tresckow, Bastian, María Ferreri, Andrés José, Teshima, Takanori, Patten, Piers E. M., McGuirk, Joseph P., Petzer, Andreas L., Offner, Fritz, Viardot, Andreas, Zinzani, Pier Luigi, Malladi, Ram, Paule, Ines, Zia, Aiesha, Awasthi, Rakesh, Han, Xia, Germano, Davide, O’Donovan, Darragh, Ramos, Roberto, Maier, Harald J., Masood, Aisha, Thieblemont, Catherine, and Schuster, Stephen J.

Published
2024
Full Text
View/download PDF

11. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study

Author

Martin, Thomas G., Moreau, Philippe, Usmani, Saad Z., Garfall, Alfred, Mateos, María-Victoria, San-Miguel, Jesús F., Oriol, Albert, Nooka, Ajay K., Rosinol, Laura, Chari, Ajai, Karlin, Lionel, Krishnan, Amrita, Bahlis, Nizar, Popat, Rakesh, Besemer, Britta, Martínez-López, Joaquín, Delforge, Michel, Trancucci, Danielle, Pei, Lixia, Kobos, Rachel, Fastenau, John, Gries, Katharine S., and van de Donk, Niels W.C.J.

Published
2024
Full Text
View/download PDF

14. Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group

Author

Sargas, Claudia, Ayala, Rosa, Larráyoz, María J., Chillón, María C., Rodriguez-Arboli, Eduardo, Bilbao, Cristina, Prados de la Torre, Esther, Martínez-Cuadrón, David, Rodríguez-Veiga, Rebeca, Boluda, Blanca, Gil, Cristina, Bernal, Teresa, Bergua, Juan, Algarra, Lorenzo, Tormo, Mar, Martínez-Sánchez, Pilar, Soria, Elena, Serrano, Josefina, Alonso-Dominguez, Juan M., García, Raimundo, Amigo, María Luz, Herrera-Puente, Pilar, Sayas, María J., Lavilla-Rubira, Esperanza, Martínez-López, Joaquín, Calasanz, María J., García-Sanz, Ramón, Pérez-Simón, José A., Gómez Casares, María T., Sánchez-García, Joaquín, Barragán, Eva, and Montesinos, Pau

Published
2023
Full Text
View/download PDF

15. Enhanced thrombin generation detected with ST-Genesia analyzer in patients with newly diagnosed multiple myeloma

Author

Velasco-Rodríguez, Diego, Martínez-Alfonzo, Inés, Velasco-Valdazo, Alberto Eterio, Revilla, Nuria, Mahíllo-Fernández, Ignacio, Askari, Elham, Castro-Quismondo, Nerea, Laso, Rosa Vidal, Domingo-González, Amalia, Serrano-López, Juana, Prieto, Elena, Rosado, Belén, Blanchard, María Jesús, Martín-Herrero, Sara, García-Raso, Aránzazu, Bueno, María Ángeles, de la Plaza, Reyes, Peñaherrera, Meybi, López, Irene Gómez, López-Jiménez, Javier, Martínez-López, Joaquín, and Llamas-Sillero, Pilar

Published
2023
Full Text
View/download PDF

16. Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET/CT

Author

Jiménez-Ubieto, Ana, Poza, María, Martin-Muñoz, Alejandro, Ruiz-Heredia, Yanira, Dorado, Sara, Figaredo, Gloria, Rosa-Rosa, Juan Manuel, Rodriguez, Antonia, Barcena, Carmen, Navamuel, Laura Parrilla, Carrillo, Jaime, Sanchez, Ricardo, Rufian, Laura, Juárez, Alexandra, Rodriguez, Margarita, Wang, Chongwu, de Toledo, Paula, Grande, Carlos, Mollejo, Manuela, Casado, Luis-Felipe, Calbacho, María, Baumann, Tycho, Rapado, Inmaculada, Gallardo, Miguel, Sarandeses, Pilar, Ayala, Rosa, Martínez-López, Joaquín, and Barrio, Santiago

Published
2023
Full Text
View/download PDF

17. Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP)

Author

Alegre, Adrián, Benzo, Gonzalo, Alonso, Rafael, Martínez-López, Joaquín, Jimenez-Ubieto, Ana, Cuéllar, Clara, Askari, Elham, Prieto, Elena, Aláez, Concepción, Aguado, Beatriz, Velasco, Alberto, Krsnik, Isabel, Bocanegra, Ana, Llorente, Laura, Muñoz-Linares, Cristina, Morales, Ana, Giménez, Eugenio, Iglesias, Rebeca, Martínez-Chamorro, Carmen, Alonso, Aránzazu, Jiménez-Montes, Carmen, and Blanchard, María J.

Published
2023
Full Text
View/download PDF

18. Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma

Author

Rosiñol, Laura, Oriol, Albert, Ríos, Rafael, Blanchard, María Jesús, Jarque, Isidro, Bargay, Joan, Hernández, Miguel Teodoro, Cabañas, Valentín, Carrillo-Cruz, Estrella, Sureda, Anna, Martínez-López, Joaquín, Krsnik, Isabel, González, Maria Esther, Casado, Luis Felipe, Martí, Josep María, Encinas, Cristina, de Arriba, Felipe, Palomera, Luis, Sampol, Antonia, González-Montes, Yolanda, Cabezudo, Elena, Paiva, Bruno, Puig, Noemí, Cedena, María Teresa, de la Cruz, Javier, Mateos, María-Victoria, San Miguel, Jesús, Lahuerta, Juan José, and Bladé, Joan

Published
2023
Full Text
View/download PDF

19. Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma

Author

Alonso, Rafael, Cedena, María-Teresa, Wong, Sandy, Shah, Nina, Ríos-Tamayo, Rafael, Moraleda, José M, López-Jiménez, Javier, García, Cristina, Bahri, Natasha, Valeri, Antonio, Sánchez, Ricardo, Collado-Yurrita, Luis, Martin, Thomas, Wolf, Jeffrey, Lahuerta, Juan-José, and Martínez-López, Joaquín

Subjects
Cancer, Rare Diseases, Hematology, Clinical Research, Evaluation of treatments and therapeutic interventions, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, 6.1 Pharmaceuticals, Humans, Lenalidomide, Multiple Myeloma, Neoplasm, Residual, Retrospective Studies, Treatment Outcome
Abstract

Lenalidomide is an immunomodulatory drug approved for maintenance treatment in newly diagnosed multiple myeloma, and it has been shown to improve progression-free survival (PFS) and, in several studies, overall survival. Nevertheless, the impact of prolonged treatment with lenalidomide on the kinetics of minimal residual disease (MRD) and its prognostic impact have not been studied in depth. To obtain better knowledge in this regard, we retrospectively analyzed 139 patients who received lenalidomide maintenance in real-world clinical practice and whose MRD levels were observed during the treatment period by multiparametric flow cytometry or next-generation sequencing with a sensitivity of at least 10-4. Lenalidomide maintenance correlated with an increased depth of the disease response, with 38.1% of patients achieving maximal response during maintenance. Moreover, 34.3% of patients who were MRD positive after induction treatment achieved MRD-negative status during maintenance and ultimately had improved PFS. Sequential MRD assessments identified patients with progressively decreasing MRD levels who also had better PFS outcomes, compared with patients not showing a decreasing pattern of MRD. These results support the role of maintenance therapy, not only to sustain, but also to increase the depth of disease response with a PFS benefit. In addition, MRD monitoring during maintenance identifies patients with better prognosis and may help in their clinical management.

Published
2020

20. CNL and aCML should be considered as a single entity based on molecular profiles and outcomes

Author

Carreño-Tarragona, Gonzalo, Álvarez-Larrán, Alberto, Harrison, Claire, Martínez-Ávila, José Carlos, Hernández-Boluda, Juan Carlos, Ferrer-Marín, Francisca, Radia, Deepti H., Mora, Elvira, Francis, Sebastian, González-Martínez, Teresa, Goddard, Kathryn, Pérez-Encinas, Manuel, Narayanan, Srinivasan, Raya, José María, Singh, Vikram, Gutiérrez, Xabier, Toth, Peter, Amat-Martínez, Paula, Mcilwaine, Louisa, Alobaidi, Magda, Mayani, Karan, McGregor, Andrew, Stuckey, Ruth, Psaila, Bethan, Segura, Adrián, Alvares, Caroline, Davidson, Kerri, Osorio, Santiago, Cutting, Robert, Sweeney, Caroline P., Rufián, Laura, Moreno, Laura, Cuenca, Isabel, Smith, Jeffery, Morales, María Luz, Gil-Manso, Rodrigo, Koutsavlis, Ioannis, Wang, Lihui, Mead, Adam J., Rozman, María, Martínez-López, Joaquín, Ayala, Rosa, and Cross, Nicholas C. P.

Published
2023
Full Text
View/download PDF

21. Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia

Author

Simoes, Catia, Chillon, Maria-Carmen, Martínez-Cuadrón, David, Calasanz, Maria-José, Vridiales, María-Belén, Vazquez, Iria, Hernández-Ruano, Montserrat, Ariceta, Beñat, Aguirre-Ruiz, Paula, Burgos, Leire, Alignani, Diego, Sarvide, Sarai, Villar, Sara, Pierola, Ana Alfonso, Prosper, Felipe, Ayala, Rosa, Martínez-López, Joaquin, Bergua Burgues, Juan Miguel, Vives, Susana, Perez-Simon, Jose A., Garcia-Fortes, Maria, Bernal del Castillo, Teresa, Colorado, Mercedes, Olave, Mayte, Rodríguez-Gutiérrez, Juan I., Labrador, Jorge, González, Marcos, San-Miguel, Jesús F., Sanz, Miguel Ángel, Montesinos, Pau, and Paiva, Bruno

Published
2023
Full Text
View/download PDF

23. Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma

Author

Salles, Gilles, Schuster, Stephen J., Dreyling, Martin, Fischer, Luca, Kuruvilla, John, Patten, Piers E. M., von Tresckow, Bastian, Smith, Sonali M., Jiménez-Ubieto, Ana, Davis, Keith L., Anjos, Carla, Chu, Jufen, Zhang, Jie, Lobetti Bodoni, Chiara, Thieblemont, Catherine, Fowler, Nathan H., Dickinson, Michael, Martínez-López, Joaquin, Wang, Yucai, and Link, Brian K.

Published
2022
Full Text
View/download PDF

25. Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome–positive acute lymphoblastic leukemia

Author

Ribera, Josep-Maria, García-Calduch, Olga, Ribera, Jordi, Montesinos, Pau, Cano-Ferri, Isabel, Martínez, Pilar, Esteve, Jordi, Esteban, Daniel, García-Fortes, María, Alonso, Natalia, González-Campos, José, Bermúdez, Arancha, Torrent, Anna, Genescà, Eulàlia, Mercadal, Santiago, Martínez-Lopez, Joaquín, and García-Sanz, Ramón

Published
2022
Full Text
View/download PDF

26. Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry study.

Author

Lloret‐Madrid, Pilar, Boluda, Blanca, Martínez‐López, Joaquín, Bergua, Juan, Rodriguez Arboli, Eduardo, Labrador, Jorge, Sossa, Claudia, Gil, Cristina, Algarra, Lorenzo, Lavilla‐Rubira, Esperanza, Serrano, Josefina, de Rueda, Beatriz, Ibañez, Francisco, González González, Bernardo J., Amigo, María Luz, García Belmonte, Daniel, Rodríguez‐Medina, Carlos, Gómez‐Roncero, María I., Colorado, Mercedes, and López Lorenzo, José L.

Subjects
HEMATOPOIETIC stem cell transplantation, LEUKOCYTE count, ACUTE myeloid leukemia, STEM cell transplantation, MYELODYSPLASTIC syndromes
Abstract

Background: Patients with secondary acute myeloid leukemia who previously received hypomethylating agents for prior myeloid neoplasms (HMA‐sAML) face a dismal prognosis. Methods: The authors analyze the characteristics, therapeutic approaches, and outcomes of patients with HMA‐sAML from the Programa Español para el Tratamiento de Hemopatías Malignas (PETHEMA) registry. Results: A total of 479 patients were included, mostly from prior myelodysplastic syndrome (84%). Frontline therapy consisted of intensive chemotherapy (IC) in 31%, low‐dose cytarabine‐based in 19%, supportive care and clinical trial 17% each, and HMA‐based therapy in 12% and 4% in venetoclax‐based regimen. Complete remission was achieved in 95 patients (27%), with higher rate among IC and venetoclax‐based groups (44% and 41%, respectively). The median overall survival (OS) was 4.93 months, with 7.68 months for IC patients, 7.82 months after HMA monotherapy, and 4.66 months after venetoclax‐based regimens. Patients who underwent allogeneic hematopoietic stem cell transplantation in first remission (n = 33, 9%) had a better survival outcome (median OS not reached). Multivariate analyses identified age (≥65 years), Eastern Cooperative Oncology Group >2, higher white blood cell count, and adverse risk cytogenetic as adverse prognostic factors, whereas NPM1 mutation was a favorable factor. Conclusions: Patients with HMA‐sAML have a poor prognosis and suboptimal outcomes with conventional treatments, including BCL2 inhibitors, highlighting the need for clinical trials targeting this population. This study analyzes the characteristics and outcomes of adults with secondary acute myeloid leukemia who previously received hypomethylating agents for prior myeloid neoplasms (HMA‐sAML). This analysis of 479 patients from the PETHEMA registry shows a poor overall survival of 4.93 months with suboptimal outcomes, highlighting the unmet clinical need for this population. Whenever is feasible, fit HMA‐sAML patients should undergo an allo‐hematopoietic stem cell transplantation in first remission. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

27. Expression profile of Bcl‐2 family proteins in newly diagnosed multiple myeloma patients.

Author

De Ramón, Cristina, Rojas, Elizabeta A., Misiewicz‐Krzeminska, Irena, Cardona‐Benavides, Ignacio J., Cuadrado, Myriam, Isidro, Isabel, Calasanz, María‐José, Fernandez, Manuela, García‐Sanz, Ramón, Puig, Noemi, Cedena, M. Teresa, Paiva, Bruno, Rosiñol, Laura, Martínez‐López, Joaquín, Bladé, Joan, Lahuerta, Juan J., San Miguel, Jesús F., Mateos, María V., Corchete, Luis A., and Gutiérrez, Norma C.

Published
2024
Full Text
View/download PDF

28. Analysis of the factors predicting clinical response to tocilizumab therapy in patients with severe COVID-19

Author

San-Juan, Rafael, Fernández-Ruiz, Mario, López-Medrano, Francisco, Carretero, Octavio, Lalueza, Antonio, Maestro de la Calle, Guillermo, Pérez-Jacoiste Asín, María Asunción, Bueno, Héctor, Caro-Teller, José Manuel, Catalán, Mercedes, de la Calle, Cristina, García-García, Rocío, Gómez, Carlos, Laguna-Goya, Rocío, Lizasoáin, Manuel, Martínez-López, Joaquín, Origüen, Julia, Sevillano, Ángel, Gutiérrez, Eduardo, de Miguel, Borja, Aguilar, Fernando, Parra, Patricia, Ripoll, Mar, Ruiz-Merlo, Tamara, Trujillo, Hernando, Pablos, José Luis, Paz-Artal, Estela, Lumbreras, Carlos, and Aguado, José María

Published
2022
Full Text
View/download PDF

29. Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry

Author

Hernández-Boluda, Juan-Carlos, Martínez-Cuadrón, David, Pereira, Arturo, Rodríguez-Veiga, Rebeca, Boluda, Blanca, Gil, Cristina, Casal-Marini, Sandra, Serrano, Josefina, Martínez-López, Joaquín, Bergua, Juan, Algarra, Lorenzo, Bernal, Teresa, López-Lorenzo, Jose-Luis, Colorado, Mercedes, López, Aurelio, Tormo, Mar, Sayas, María-José, Trigo, Fernanda, López-Pavía, María, Pérez-Simón, José-Antonio, Lavilla-Rubira, Esperanza, Rodríguez-Medina, Carlos, Rodríguez-Gutiérrez, Juan-Ignacio, Sanz-Caballer, Miguel-Angel, and Montesinos, Pau

Published
2022
Full Text
View/download PDF

30. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study

Author

Schjesvold, Fredrik, Delimpasi, Sosana, Robak, Pawel, Coriu, Daniel, Nikolayeva, Anna, Tomczak, Waldemar, Pour, Ludek, Spicka, Ivan, Dimopoulos, Meletios-Athanasios, Masszi, Tamas, Doronin, Vadim, Minarik, Jiri, Salogub, Galina, Alekseeva, Yulia, Maisnar, Vladimir, Mikala, Gabor, Rosinol, Laura, Konstantinova, Tatiana, Lazzaro, Antonio, Liberati, Anna Marina, Symeonidis, Anargyros, Gatt, Moshe, Illes, Arpad, Abdulhaq, Haifaa, Dungarwalla, Moez, Grosicki, Sebastian, Hajek, Roman, Leleu, Xavier, Myasnikov, Alexander, Richardson, Paul G., Avivi, Irit, Deeren, Dries, Gironella, Mercedes, Hernandez-Garcia, Miguel Teodoro, Martinez Lopez, Joaquin, Newinger-Porte, Muriel, Ribas, Paz, Samoilova, Olga, Voog, Eric, Arnao-Herraiz, Mario, Carrillo-Cruz, Estrella, Corradini, Paolo, Dodlapati, Jyothi, Granell Gorrochategui, Miquel, Huang, Shang-Yi, Jenner, Matthew, Karlin, Lionel, Kim, Jin Seok, Kopacz, Agnieszka, Medvedeva, Nadezhda, Min, Chang-Ki, Mina, Roberto, Palk, Katrin, Shin, Ho-Jin, Sohn, Sang Kyun, Sonneveld, Pieter, Tache, Jason, Anagnostopoulos, Achilles, Arguiñano, Jose-Maria, Cavo, Michele, Filicko, Joanne, Garnes, Margaret, Halka, Janusz, Herzog-Tzarfati, Kathrin, Ipatova, Natalia, Kim, Kihyun, Krauth, Maria-Theresa, Kryuchkova, Irina, Lazaroiu, Mihaela Cornelia, Luppi, Mario, Proydakov, Andrei, Rambaldi, Alessandro, Rudzianskiene, Milda, Yeh, Su-Peng, Alcalá-Peña, Maria Magdalena, Alegre Amor, Adrian, Alizadeh, Hussain, Bendandi, Maurizio, Brearton, Gillian, Brown, Randall, Cavet, Jim, Dally, Najib, Egyed, Miklos, Hernández-Rivas, José Ángel, Kaare, Ain, Karsenti, Jean-Michel, Kloczko, Janusz, Kreisle, William, Lee, Je-Jung, Legiec, Wojciech, Machherndl-Spandl, Sigrid, Manda, Sudhir, Mateos, Maria-Victoria, Moiseev, Ivan, Moreb, Jan, Nagy, Zsolt, Nair, Santosh, Oriol-Rocafiguera, Albert, Osswald, Michael, Otero-Rodriguez, Paula, Peceliunas, Valdas, Plesner, Torben, Rey, Philippe, Rossi, Giuseppe, Stevens, Don, Suriu, Celia, Tarella, Corrado, Verlinden, Anke, Zannetti, Alain, Schjesvold, Fredrik H, Pour, Luděk, Špička, Ivan, Mikala, Gábor, Rosiñol, Laura, Symeonidis, Argiris, Moody, Victoria, Thuresson, Marcus, Byrne, Catriona, Harmenberg, Johan, Bakker, Nicolaas A, Hájek, Roman, and Richardson, Paul G

Published
2022
Full Text
View/download PDF

31. FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology

Author

Botta, Cirino, Maia, Catarina, Garcés, Juan-José, Termini, Rosalinda, Perez, Cristina, Manrique, Irene, Burgos, Leire, Zabaleta, Aintzane, Alignani, Diego, Sarvide, Sarai, Merino, Juana, Puig, Noemi, Cedena, María-Teresa, Rossi, Marco, Tassone, Pierfrancesco, Gentile, Massimo, Correale, Pierpaolo, Borrello, Ivan, Terpos, Evangelos, Jelinek, Tomas, Paiva, Artur, Roccaro, Aldo, Goldschmidt, Hartmut, Avet-Loiseau, Hervé, Rosinol, Laura, Mateos, Maria-Victoria, Martinez-Lopez, Joaquin, Lahuerta, Juan-José, Bladé, Joan, San-Miguel, Jesús F., and Paiva, Bruno

Published
2022
Full Text
View/download PDF

32. Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA

Author

Sánchez, Ricardo, Dorado, Sara, Ruíz-Heredia, Yanira, Martín-Muñoz, Alejandro, Rosa-Rosa, Juan Manuel, Ribera, Jordi, García, Olga, Jimenez-Ubieto, Ana, Carreño-Tarragona, Gonzalo, Linares, María, Rufián, Laura, Juárez, Alexandra, Carrillo, Jaime, Espino, María José, Cáceres, Mercedes, Expósito, Sara, Cuevas, Beatriz, Vanegas, Raúl, Casado, Luis Felipe, Torrent, Anna, Zamora, Lurdes, Mercadal, Santiago, Coll, Rosa, Cervera, Marta, Morgades, Mireia, Hernández-Rivas, José Ángel, Bravo, Pilar, Serí, Cristina, Anguita, Eduardo, Barragán, Eva, Sargas, Claudia, Ferrer-Marín, Francisca, Sánchez-Calero, Jorge, Sevilla, Julián, Ruíz, Elena, Villalón, Lucía, del Mar Herráez, María, Riaza, Rosalía, Magro, Elena, Steegman, Juan Luis, Wang, Chongwu, de Toledo, Paula, García-Gutiérrez, Valentín, Ayala, Rosa, Ribera, Josep-Maria, Barrio, Santiago, and Martínez-López, Joaquín

Published
2022
Full Text
View/download PDF

35. Phase 2 Clinical Trial of Infusing Haploidentical K562-mb15-41BBL–Activated and Expanded Natural Killer Cells as Consolidation Therapy for Pediatric Acute Myeloblastic Leukemia

Author

Gómez García, Lara Maria, Escudero, Adela, Mestre, Carmen, Fuster Soler, Jose L., Martínez, Antonia Pascual, Vagace Valero, Jose M., Vela, María, Ruz, Beatriz, Navarro, Alfonso, Fernández, Lucia, Fernández, Adrián, Leivas, Alejandra, Martínez-López, Joaquin, Ferreras, Cristina, De Paz, Raquel, Blanquer, Miguel, Galán, Victor, González, Berta, Corral, Dolores, Sisinni, Luisa, Mirones, Isabel, Balas, Antonio, Vicario, José Luis, Valle, Paula, Borobia, Alberto M., and Pérez-Martínez, Antonio

Published
2021
Full Text
View/download PDF

36. Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: A single-center retrospective study

Author

López-Medrano, Francisco, Pérez-Jacoiste Asín, María Asunción, Fernández-Ruiz, Mario, Carretero, Octavio, Lalueza, Antonio, Maestro de la Calle, Guillermo, Caro, José Manuel, de la Calle, Cristina, Catalán, Mercedes, García-García, Rocío, Martínez-López, Joaquín, Origüen, Julia, Ripoll, Mar, San Juan, Rafael, Trujillo, Hernando, Sevillano, Ángel, Gutiérrez, Eduardo, de Miguel, Borja, Aguilar, Fernando, Gómez, Carlos, Silva, José Tiago, García-Ruiz de Morales, Daniel, Saro-Buendía, Miguel, Marrero-Sánchez, Ángel, Chiara-Graciani, Guillermo, Bueno, Héctor, Paz-Artal, Estela, Lumbreras, Carlos, Pablos, José L., and Aguado, José María

Published
2021
Full Text
View/download PDF

37. Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study

Author

de la Calle, Cristina, López-Medrano, Francisco, Pablos, José Luis, Lora-Tamayo, Jaime, Maestro-de la Calle, Guillermo, Sánchez-Fernández, Marcos, Fernández-Ruiz, Mario, Pérez-Jacoiste Asín, María Asunción, Caro-Teller, José Manuel, García-García, Rocío, Catalán, Mercedes, Martínez-López, Joaquín, Sevillano, Ángel, Origüen, Julia, Ripoll, Mar, San Juan, Rafael, Lalueza, Antonio, de Miguel, Borja, Carretero, Octavio, Aguilar, Fernando, Gómez, Carlos, Paz-Artal, Estela, Bueno, Héctor, Lumbreras, Carlos, and Aguado, José María

Published
2021
Full Text
View/download PDF

38. Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial

Author

Simoes, Catia, Paiva, Bruno, Martínez-Cuadrón, David, Bergua, Juan-Miguel, Vives, Susana, Algarra, Lorenzo, Tormo, Mar, Martinez, Pilar, Serrano, Josefina, Herrera, Pilar, Ramos, Fernando, Salamero, Olga, Lavilla, Esperanza, Gil, Cristina, Lopez, Jose-Luis, Vidriales, Maria-Belen, Labrador, Jorge, Falantes, Jose-Francisco, Sayas, María-José, Ayala, Rosa, Martinez-Lopez, Joaquin, Villar, Sara, Calasanz, Maria-Jose, Prosper, Felipe, San-Miguel, Jesús F., Sanz, Miguel Ángel, and Montesinos, Pau

Published
2021
Full Text
View/download PDF

39. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma

Author

Goicoechea, Ibai, Puig, Noemi, Cedena, Maria-Teresa, Burgos, Leire, Cordón, Lourdes, Vidriales, María-Belén, Flores-Montero, Juan, Gutierrez, Norma C., Calasanz, Maria-Jose, Ramos, Maria-Luisa Martin, Lara-Astiaso, David, Vilas-Zornoza, Amaia, Alignani, Diego, Rodriguez, Idoia, Sarvide, Sarai, Alameda, Daniel, Garcés, Juan José, Rodriguez, Sara, Fresquet, Vicente, Celay, Jon, Garcia-Sanz, Ramón, Martinez-Lopez, Joaquin, Oriol, Albert, Rios, Rafael, Martin-Sanchez, Jesus, Martinez-Martinez, Rafael, Sarra, Josep, Hernandez, Miguel-Teodoro, de la Rubia, Javier, Krsnik, Isabel, Moraleda, Jose-Maria, Palomera, Luis, Bargay, Joan, Martinez-Climent, Jose-Angel, Orfao, Alberto, Rosiñol, Laura, Mateos, Maria-Victoria, Lahuerta, Juan-José, Blade, Joan, San Miguel, Jesús, and Paiva, Bruno

Published
2021
Full Text
View/download PDF

40. A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients

Author

Martínez Sánchez, María P., Megías-Vericat, Juan Eduardo, Rodríguez-Veiga, Rebeca, Vives, Susana, Bergua, Juan Miguel, Torrent, Anna, Suárez-Varela, Sara, Boluda, Blanca, Martínez-López, Joaquín, Cano-Ferri, Isabel, Acuña-Cruz, Evelyn, Torres-Miñana, Laura, Martín-Herreros, Beatriz, Serrano, Alfons, Sempere, Amparo, Barragán, Eva, Sargas, Claudia, Sanz, Miguel, Martínez-Cuadrón, David, and Montesinos, Pau

Published
2021
Full Text
View/download PDF

41. Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?

Author

Martínez-Cuadrón, David, Serrano, Josefina, Gil, Cristina, Tormo, Mar, Martínez-Sánchez, Pilar, Pérez-Simón, José A., García-Boyero, Raimundo, Rodríguez-Medina, Carlos, López-Pavía, María, Benavente, Celina, Bergua, Juan, Lavilla-Rubira, Esperanza, Amigo, María L., Herrera, Pilar, Alonso-Domínguez, Juan M., Bernal, Teresa, Colorado, Mercedes, Sayas, María J., Algarra, Lorenzo, Vidriales, María B., Rodríguez-Macías, Gabriela, Vives, Susana, Pérez-Encinas, Manuel M., López, Aurelio, Noriega, Víctor, García-Fortes, María, Ramos, Fernando, Rodríguez-Gutiérrez, Juan I., Costilla-Barriga, Lisette, Labrador, Jorge, Boluda, Blanca, Rodríguez-Veiga, Rebeca, Martínez-López, Joaquín, Sanz, Miguel A., and Montesinos, Pau

Published
2021
Full Text
View/download PDF

43. Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry.

Author

Labrador, Jorge, Martínez‐Cuadrón, David, Boluda, Blanca, Serrano, Josefina, Gil, Cristina, Pérez‐Simón, José A., Bernal, Teresa, Bergua, Juan M., Martínez‐López, Joaquín, Rodríguez‐Medina, Carlos, Vidriales, María B., García‐Boyero, Raimundo, Algarra, Lorenzo, Polo, Marta, Sayas, María J., Tormo, Mar, Alonso‐Domínguez, Juan M., Herrera, Pilar, Lavilla, Esperanza, and Ramos, Fernando

Subjects
ACUTE myeloid leukemia, TREATMENT effectiveness, GENETIC disorder diagnosis, MOLECULAR diagnosis, OVERALL survival
Abstract

Background: There are no studies assessing the evolution and patterns of genetic studies performed at diagnosis in acute myeloid leukemia (AML) patients. Such studies could help to identify potential gaps in our present diagnostic practices, especially in the context of increasingly complex procedures and classifications. Methods: The REALMOL study (NCT05541224) evaluated the evolution, patterns, and clinical impact of performing main genetic and molecular studies performed at diagnosis in 7285 adult AML patients included in the PETHEMA AML registry (NCT02607059) between 2000 and 2021. Results: Screening rates increased for all tests across different time periods (2000–2007, 2008–2016, and 2017–2021) and was the most influential factor for NPM1, FLT3‐ITD, and next‐generation sequencing (NGS) determinations: NPM1 testing increased from 28.9% to 72.8% and 95.2% (p <.001), whereas FLT3‐ITD testing increased from 38.1% to 74.1% and 95.9% (p <.0001). NGS testing was not performed between 2000–2007 and only reached 3.5% in 2008–2016, but significantly increased to 72% in 2017–2021 (p <.001). Treatment decision was the most influential factor to perform karyotype (odds ratio [OR], 6.057; 95% confidence interval [CI], 4.702–7.802), and fluorescence in situ hybridation (OR, 2.273; 95% CI, 1.901–2.719) studies. Patients ≥70 years old or with an Eastern Cooperative Oncology Group ≥2 were less likely to undergo these diagnostic procedures. Performing genetic studies were associated with a favorable impact on overall survival, especially in patients who received intensive chemotherapy. Conclusions: This unique study provides relevant information about the evolving landscape of genetic and molecular diagnosis for adult AML patients in real‐world setting, highlighting the increased complexity of genetic diagnosis over the past 2 decades. A retrospective analysis of 7285 cases over 2 decades. This study explores the evolution of diagnostic practices in acute myeloid leukemia patients, highlighting factors influencing test implementation and their association with patient outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

44. Real-World Impact of Deep Targeted Sequencing on Erythrocytosis and Thrombocytosis Diagnosis: A Reference Centre Experience.

Author

Blanco-Sánchez, Alberto, Gil-Manso, Rodrigo, de Nicolás, Rodrigo, López-Muñoz, Nieves, Colmenares, Rafael, Mas, Reyes, Sánchez, Ricardo, Rapado, Inmaculada, Martínez-López, Joaquín, Díaz, Rosa Ayala, and Carreño-Tarragona, Gonzalo

Subjects
POLYCYTHEMIA, BIOPSY, BONE marrow, RESEARCH funding, RETROSPECTIVE studies, DESCRIPTIVE statistics, GENES, POLYCYTHEMIA vera, GENE expression profiling, THROMBOCYTOSIS, GENETIC mutation, SEQUENCE analysis, DISEASE complications
Abstract

Simple Summary: Around 70% of cases of erythrocytosis are categorised as "idiopathic" after excluding secondary causes and polycythaemia vera. A similar situation arises in the setting of thrombocytosis, with even a 15% of essential thrombocythemia lacking canonical mutations. Previous studies have shown that a deeper investigation of these patients can unmask underlying primary conditions (such as familial disorders or a clonal disease without canonical mutations). The role of next-generation sequencing (NGS) in their diagnosis has been explored in a retrospective manner, showing promising results. In this study, we reviewed the impact of NGS performed in our centre on the diagnosis of erythrocytosis and thrombocytosis (117 and 58 patients, respectively). Our findings showed that few patients benefited from this test, since only 11.9% and 25.9% showed a variant leading to diagnosis of a primary disorder, respectively. However, we believe that this yield could be improved through a better selection prior to NGS. Despite advances in diagnosis of erythrocytosis and thrombocytosis due to driver mutation testing, many cases remain classified as "idiopathic". This can be explained by the absence of an evident secondary cause, inconclusive bone marrow biopsy or neglection of family history. Analysis of a broad panel of genes through next-generation sequencing (NGS) could improve diagnostic work-up identifying underlying genetic causes. We reviewed the results of NGS performed in our laboratory and its diagnostic impact on 117 patients with unexplained erythrocytosis and 58 with unexplained thrombocytosis; six patients (5.1%) were diagnosed with polycythaemia vera (PV) and 8 (6.8%) with familial erythrocytosis after NGS testing. Low EPO and a family history seemed to predict a positive result, respectively. However, a greater percentage of patients were ultimately diagnosed with secondary erythrocytosis (36%), remained as idiopathic (28.2%) or were self-limited (15%). The yield of NGS was shown to be slightly higher in patients with thrombocytosis, as 15 (25.9%) were diagnosed with essential thrombocythemia (ET) or familial thrombocytosis after variant detection; previous research has shown similar results, but most of them carried out NGS retrospectively, while the present study exhibits the performance of this test in a real-world setting. Overall, the low rate of variant detection and its poor impact on diagnostic work-up highlights the need for a thorough screening prior to NGS, in order to improve its yield. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

45. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set

Author

Chari, Ajai, Samur, Mehmet Kemal, Martinez-Lopez, Joaquin, Cook, Gordon, Biran, Noa, Yong, Kwee, Hungria, Vania, Engelhardt, Monika, Gay, Francesca, García Feria, Ana, Oliva, Stefania, Oostvogels, Rimke, Gozzetti, Alessandro, Rosenbaum, Cara, Kumar, Shaji, Stadtmauer, Edward A., Einsele, Hermann, Beksac, Meral, Weisel, Katja, Anderson, Kenneth C., Mateos, María-Victoria, Moreau, Philippe, San-Miguel, Jesus, Munshi, Nikhil C., and Avet-Loiseau, Hervé

Published
2020
Full Text
View/download PDF

47. IL-6–based mortality risk model for hospitalized patients with COVID-19

Author

Laguna-Goya, Rocio, Utrero-Rico, Alberto, Talayero, Paloma, Lasa-Lazaro, Maria, Ramirez-Fernandez, Angel, Naranjo, Laura, Segura-Tudela, Alejandro, Cabrera-Marante, Oscar, Rodriguez de Frias, Edgar, Garcia-Garcia, Rocio, Fernández-Ruiz, Mario, Aguado, Jose Maria, Martinez-Lopez, Joaquin, Lopez, Elena Ana, Catalan, Mercedes, Serrano, Antonio, and Paz-Artal, Estela

Published
2020
Full Text
View/download PDF

49. Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

Author

Perez, Cristina, Botta, Cirino, Zabaleta, Aintzane, Puig, Noemi, Cedena, Maria-Teresa, Goicoechea, Ibai, Alameda, Daniel, San José-Eneriz, Edurne, Merino, Juana, Rodríguez-Otero, Paula, Maia, Catarina, Alignani, Diego, Maiso, Patricia, Manrique, Irene, Lara-Astiaso, David, Vilas-Zornoza, Amaia, Sarvide, Sarai, Riillo, Caterina, Rossi, Marco, Rosiñol, Laura, Oriol, Albert, Blanchard, María-Jesús, Rios, Rafael, Sureda, Anna, Martin, Jesus, Martinez, Rafael, Bargay, Joan, de la Rubia, Javier, Hernandez, Miguel-Teodoro, Martinez-Lopez, Joaquin, Orfao, Alberto, Agirre, Xabier, Prosper, Felipe, Mateos, Maria-Victoria, Lahuerta, Juan-José, Blade, Joan, San-Miguel, Jesús F., and Paiva, Bruno

Published
2020
Full Text
View/download PDF

50. Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma

Author

Maia, Catarina, Puig, Noemi, Cedena, Maria-Teresa, Goicoechea, Ibai, Valdes-Mas, Rafael, Vazquez, Iria, Chillon, Maria-Carmen, Aguirre, Paula, Sarvide, Sarai, Gracia-Aznárez, Francisco Javier, Alkorta, Gorka, Calasanz, Maria-Jose, Garcia-Sanz, Ramon, Gonzalez, Marcos, Gutierrez, Norma C., Martinez-Lopez, Joaquin, Perez, José J., Merino, Juana, Moreno, Cristina, Burgos, Leire, Alignani, Diego, Botta, Cirino, Prosper, Felipe, Matarraz, Sergio, Orfao, Alberto, Oriol, Albert, Teruel, Ana-Isabel, de Paz, Raquel, de Arriba, Felipe, Hernandez, Miguel T., Palomera, Luis, Martinez, Rafael, Rosiñol, Laura, Mateos, Maria-Victoria, Lahuerta, Juan-Jose, Blade, Joan, San Miguel, Jesus F., and Paiva, Bruno

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results